70 related articles for article (PubMed ID: 16118939)
1. Safety and Efficacy of Oral Hydroxychloroquine in the Treatment of Ophthalmic Disease Associated with Sjögren's Syndrome.
Fang W; Qingqing Z; Qihui L; Bing Z; Xinyue H; Jie X
Altern Ther Health Med; 2023 Nov; 29(8):656-662. PubMed ID: 37678871
[TBL] [Abstract][Full Text] [Related]
2. Effect of Oral Pilocarpine in Treating Severe Dry Eye in Patients With Sjögren Syndrome.
Kawakita T; Shimmura S; Tsubota K
Asia Pac J Ophthalmol (Phila); 2015; 4(2):101-5. PubMed ID: 26065354
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of a new water-free topical cyclosporine 0.1% solution for optimizing the ocular surface in patients with dry eye and cataract.
Akpek EK; Sheppard JD; Hamm A; Angstmann-Mehr S; Krösser S
J Cataract Refract Surg; 2024 Jun; 50(6):644-650. PubMed ID: 38334413
[TBL] [Abstract][Full Text] [Related]
4. Superficial mucoceles in cancer patients: a retrospective series from a Stomatology unit.
Heguedusch D; Tomo S; Almeida OP; Alves FA
Med Oral Patol Oral Cir Bucal; 2023 Nov; 28(6):e562-e566. PubMed ID: 37471298
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Subjective Responses to Cyclosporine 0.05% Versus Lifitegrast 5.0% in Individuals With Dry Eye Disease.
Locatelli EVT; Acuna KA; Betz J; Tovar AA; Galor A
Cornea; 2024 Jan; 43(1):88-94. PubMed ID: 36853599
[TBL] [Abstract][Full Text] [Related]
6. Cyclosporine 0.1% (Ikervis
Rahhal-Ortuño M; Fernández-Santodomingo AS; Villena-Alvarado C; Marín-Payá E; Aguilar-González M; García-Delpech S
Taiwan J Ophthalmol; 2020; 10(4):309-311. PubMed ID: 33437608
[TBL] [Abstract][Full Text] [Related]
7. Perfluorohexyloctane: Do we really need a PFAS for the treatment of Dry Eye Disease?
García-Blasco C; Domingo-Echaburu S; Orive G; Lertxundi U
Sci Total Environ; 2023 Nov; 901():165936. PubMed ID: 37532053
[No Abstract] [Full Text] [Related]
8. Inflammation mechanism and anti-inflammatory therapy of dry eye.
Chu L; Wang C; Zhou H
Front Med (Lausanne); 2024; 11():1307682. PubMed ID: 38420354
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of topical cyclosporine 0.1% in moderate-to-severe dry eye disease refractory to topical cyclosporine 0.05% regimen.
Chan YH; Sun CC
Taiwan J Ophthalmol; 2023; 13(1):68-74. PubMed ID: 37252163
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of using topical cyclosporine A for treatment of moderate to severe dry eye disease.
Othman TM; Mousa A; Gikandi PW; AbdelMabod M; Abdelrahman AM
Saudi J Ophthalmol; 2018; 32(3):217-221. PubMed ID: 30224886
[TBL] [Abstract][Full Text] [Related]
11. Systemic immunomodulatory therapy in severe dry eye secondary to inflammation.
Cordero-Coma M; Anzaar F; Sobrin L; Foster CS
Ocul Immunol Inflamm; 2007; 15(2):99-104. PubMed ID: 17558834
[TBL] [Abstract][Full Text] [Related]
12. Treatment of dry eye disease by the non-ophthalmologist.
Foulks GN
Rheum Dis Clin North Am; 2008 Nov; 34(4):987-1000, x. PubMed ID: 18984417
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Sjögren's syndrome-associated dry eye an evidence-based review.
Akpek EK; Lindsley KB; Adyanthaya RS; Swamy R; Baer AN; McDonnell PJ
Ophthalmology; 2011 Jul; 118(7):1242-52. PubMed ID: 21459453
[TBL] [Abstract][Full Text] [Related]
14. [A 0,05% cyclosporine treatment of the advanced dry eye syndrome].
Kujawa A; Rózycki R
Klin Oczna; 2005; 107(4-6):280-6. PubMed ID: 16118939
[TBL] [Abstract][Full Text] [Related]
15. [Immunological phenomenons in the pathology of the tear film. Is cyclosporine the turn point in the Sjögren's syndrome treatment? Preliminary report].
Kujawa A; Rózycki R
Klin Oczna; 2004; 106(3 Suppl):489-91. PubMed ID: 15636245
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of topical cyclosporine 0.05% in the treatment of dry eye associated with graft versus host disease.
Rao SN; Rao RD
Cornea; 2006 Jul; 25(6):674-8. PubMed ID: 17077659
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
